« Return to News | R&D Trends

Sutro, Celgene to develop next-gen ADCs and bispecific antibodies

Wednesday, December 19, 2012 09:14 AM

Sutro Biopharma, a San Francisco-based biopharmaceutical company, has formed a collaboration with Celgene, a multinational biopharmaceutical company, to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody.

Sutro will receive a substantial upfront payment, an equity investment in the company and payments for the completion of research, development and regulatory milestones. If all programs are successful, the deal could be worth over $500 million to Sutro. The company is also eligible to receive royalties on product sales.

In the collaboration, Sutro will be responsible for product design and production of preclinical materials using the company's proprietary, cell-free protein synthesis technology. 

"We are pleased to work with Celgene on multiple programs that utilize a broad spectrum of Sutro's cell free protein synthesis technology and capabilities," said William Newell, CEO of Sutro Biopharma. "The scope of this partnership showcases our novel, cell-free approach to designing, developing and manufacturing next-generation ADCs and bispecific antibodies."

Thomas Daniel, M.D., president of global research and early development, Celgene, added, "We look forward to working with the team at Sutro and to exploring their platform's potential to accelerate the discovery and development of superior multifunctional biologics."

Four Oaks Partners advised Sutro on the transaction.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.